Clostridium Difficile Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033
All the vital news, analysis, and commentary curated by our industry experts.
Clostridium Difficile Tests Market Report Overview
The Clostridium Difficile Tests market size was valued at $156 million in 2022. C. difficile is a highly contagious bacteria predominantly found in soil and can enter a person through the Fecal-oral route. The spore-forming ability of this bacteria makes it highly resistant to antibiotics. Risk factors associated with CDI are old age, recent hospital stay, and prolonged exposure to antibiotics. Symptoms of CDI are prolonged Diarrhea, abdominal pain, and tenderness, fever, and blood in stools.
Clostridium Difficile Tests Market Outlook 2022-2033 ($ Million)
For more insights on the Clostridium Difficile Tests market forecast, download a free sample report
The Clostridium Difficile Tests market research report is built to visualize quantitative market trends within in vitro diagnostics therapeutic areas. Furthermore, the model discusses in detail the impact of COVID-19 on the Clostridium Difficile Tests market for the year 2020 and beyond.
|Market Size (2022)||$156 million|
|Enquire & Decide||Discover the perfect solution for your business needs. Enquire now and let us help you make an informed decision before making a purchase.|
Clostridium Difficile Tests Market Dynamics
The Clostridium difficile tests market is expected to increase during the forecast period, largely due to increases in overall population size and thus the number of suspected infection cases. This Market is dominated by markets in North America and Europe, with fewer sales occurring in other regions. Diminished sales in the APAC, South American, and Middle East & Africa regions, continue to be negatively impacted by under-reporting of the disease and the lack of uniform testing algorithms.
While expansion of Clostridium difficile screening to asymptomatic patients would drive strong growth in the sales of these testing devices, primary participants indicate that this change in policy is unlikely to occur in the near future. Physician guidelines continue to recommend that only symptomatic patients should be tested for CDI and primary participants indicate that this advice is generally adhered to.
For additional Clostridium Difficile Tests market dynamics, download a free sample report
Clostridium Difficile Tests Market Segments
The key segments in the Clostridium Difficile Tests market are Clostridium Difficile Nucleic Acid Amplification Tests (NAATs), Clostridium Difficile Toxin Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Tests, Dual Toxin and Glutamate dehydrogenase (GDH) Enzyme Immuno Assay (EIA) Tests, Glutamate dehydrogenase (GDH) Enzyme Immuno Assay (EIA) Tests. In 2022, the Clostridium Difficile Nucleic Acid Amplification Tests (NAATs) segment dominated the market share.
The market for NAATs is considerably stronger in the US and South Korea, due to the fact that a single NAAT is sometimes used to diagnose CDI in these two countries. Additionally, the use of GDH EIA tests is strong in Europe and a number of other key markets, due to the widespread implementation of the two-step algorithm, as well as the cost-effectiveness and high positive predictive value of these devices.
Clostridium Difficile Tests Market Analysis by Segments, 2022 (%)
To know more about the Clostridium Difficile Tests market segments, download a free sample report
Clostridium Difficile Tests Market Segmentation by Regions
The key regions in the Clostridium Difficile Tests market are Asia-Pacific, Europe, the Middle East and Africa, North America, and South and Central America. In 2022, North America emerged as the leading regional segment with the US being the largest contributor to the regional market.
Growth is expected to occur in the US, Canada, and Mexico, largely due to increases in overall population size and thus the number of suspected infection cases. The US Clostridium Difficile tests IVD market is large compared to many other countries, due to strong sales of NAAT devices. Primary participants and secondary sources indicate that in many US institutions, NAAT is used as the initial method for diagnosing CDI. Conversely, in Canada and Mexico the device is used for initial testing of suspected CDI cases tend to be toxin EIA tests and GDH EIA tests, respectively.
Clostridium Difficile Tests Market Analysis by Regions, 2022 (%)
For more regional insights in the Clostridium Difficile Tests market, download a free sample report
Clostridium Difficile Tests Market – Competitive Landscape
The key companies in the Clostridium Difficile Tests market are bioMerieux SA, Meridian Bioscience Inc, TECHLAB Inc, Thermo Fisher Scientific Inc, LG Life Science LTD, Leica Microsystems Inc + Cepheid Inc, DiaSorin Molecular LLC + Luminex Corp, Microbiologics Inc, and American Type Culture Collection among others. In 2022, Leica Microsystems Inc + Cepheid Inc accounted for the highest Clostridium Difficile Tests market share and value.
Clostridium Difficile Tests Market Analysis by Companies, 2022 (%)
For more company insights into the Clostridium Difficile Tests market, download a free sample report
Segments Covered in this Report
Clostridium Difficile Tests Segment Outlook ($ Million, 2015-2033)
- Clostridium difficile Culture Tests
- Clostridium difficile Nucleic Acid Amplification Tests (NAATs)
- Clostridium difficile Toxin Enzyme Immuno Assay/Enzyme Linked Immunosorbent Assay (EIA/ELISA) Tests
- Dual Toxin and Glutamate dehydrogenase (GDH) Enzyme Immuno Assay (EIA) Tests
- Glutamate dehydrogenase (GDH) Enzyme Immuno Assay (EIA) Tests
Clostridium Difficile Tests Regional Outlook ($ Million, 2015-2033)
- Middle East and Africa
- North America
- South and Central America
Key Inclusions of the market model are –
Currently marketed Clostridium Difficile Tests market and evolving competitive landscape –
- Insightful review of the key industry trends.
- Annualized total Clostridium Difficile Tests market revenue by segment and market outlooks from 2015-2033.
- Market-level data on units, average selling prices, and market values.
Global, Regional and Country level market specific insights –
- Qualitative market-specific information is available with global trends further broken down into regional trends. In addition, GlobalData analysts provide unique country-specific insights on the market.
- SWOT analysis for the Clostridium Difficile Tests market.
- Competitive dynamics insights and trends provided for the Clostridium Difficile Tests market.
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
- Country-specific overview of the healthcare system.
- Country-specific reimbursement policies.
- Country-specific medtech regulatory landscape.
Robust methodologies and sources enable the model to provide an extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real-world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: bioMerieux SA, Meridian Bioscience Inc, TECHLAB Inc, Thermo Fisher Scientific Inc, LG Life Science LTD, Leica Microsystems Inc + Cepheid Inc, DiaSorin Molecular LLC + Luminex Corp, Microbiologics Inc, and American Type Culture Collection.
Countries covered – United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.
This Market Model gives important, expert insight you won’t find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for
- CMO executives who must have a deep understanding of the Clostridium Difficile Tests marketplace to make strategic planning and investment decisions.
- Sourcing and procurement executives must understand crucial components of the supply base in order to make decisions about supplier selection and management.
- Private equity investors that need a deeper understanding of the market to identify and value potential investment targets.
Reasons to Buy
The model will enable you to –
- Understand the impact of COVID-19 on Clostridium Difficile Tests.
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving Clostridium Difficile Tests.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the Clostridium Difficile Tests market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the company’s share of market leaders.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Track device sales in the global and country-specific Clostridium Difficile Tests market from 2015-2033.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Meridian Bioscience Inc
Thermo Fisher Scientific Inc
LG Chem Ltd
American Type Culture Collection
Frequently asked questions
What was the Clostridium Difficile Tests market size in 2022?
The Clostridium Difficile Tests market size was $156 million in 2022.
Which was the leading segment in the Clostridium Difficile Tests market?
Clostridium difficile Nucleic Acid Amplification Tests (NAATs) segment was leading the Clostridium Difficile Tests market in 2022.
Which region dominates the Clostridium Difficile Tests market share?
North America was the largest regional segment of the Clostridium Difficile Tests market in 2022.
Who are the major players in the Clostridium Difficile Tests market?
The key companies in the Clostridium Difficile Tests market are bioMerieux SA, Meridian Bioscience Inc, TECHLAB Inc, Thermo Fisher Scientific Inc, LG Life Science LTD, Leica Microsystems Inc + Cepheid Inc, DiaSorin Molecular LLC + Luminex Corp, Microbiologics Inc, and American Type Culture Collection among others.
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.
Business Intelligence & Marketing Manager, SAL Heavy Lift
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
Market Analyst & Management, Liebherr-Werk
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Head of Key Accounts, Saab AB
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Marketing Intelligence Manager, Portugal Foods
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
Head of Customer Insight and Research, Standard Chartered
Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.
I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.
I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.
Head of Consumer Sensory Insights, Givaudan
“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.
Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”
Senior Account Manager, TSYS
GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.
I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.
One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.